ANGO Earnings Preview: Options Price a ±20.0% Move
· The NYC Memo · ANGO reports 2026-10-08
AngioDynamics, Inc. reports October 8, 2026. The November 20, 2026 straddle implies ±20.01% against a 13.43% average reaction, with dealers long gamma and max pain at $15.
Live updates
Oct 8 — Ahead of earnings on October 8, 2026, ANGO spot slipped from $14.42 to $14.19 as the implied move widened from ±19.69% to ±20.01%, reflecting greater anticipated volatility around the report.
Oct 7 — Ahead of ANGO earnings on October 8, 2026, spot fell from $15.54 to $14.42 while the implied move expanded from ±18.28% to ±19.69%, implying expectations for greater post-earnings price volatility.
Oct 6 — Ahead of October 8, 2026 earnings, ANGO spot rose from $15.11 to $15.54 while the implied move narrowed from ±18.80% to ±18.28%, signaling reduced market expectations for post-release price volatility.
AngioDynamics, Inc. reports Q1 2027 results on October 8, 2026, before open. Spot is $14.19, down -6.8% over the past month. For the November 20, 2026 expiry, the options market asks for a 20.01% implied move, pricing a $2.84 straddle with atm iv at 68.8% across an implied range of $11.35 to $17.03.
That demand outstrips the average realised reaction of 13.43% across 3 prints counted, where shares finished higher 2 times and lower 1 time. Meanwhile, dealer positioning reflects a long gamma lean, with put to call open interest at 0.40 and max pain at $15. This long gamma profile dampens volatility, keeping the tape pinned into the print.
What the market will be watching
AngioDynamics reports quarterly earnings with options desks focused on procedural demand across key oncology and vascular lines. Traders will scrutinize volume trends for growth platforms like NanoKnife and Auryon against mature device categories. Gross margin stability and operational cost controls remain essential to prove earnings leverage amid supply pressures. Market participants will evaluate full-year guidance updates to assess commercial durability following recent portfolio shifts. Clinical milestones, regulatory progress, and operating cash consumption will decide the stock reaction after the release.
What the options market is pricing
| Measure | Level |
|---|---|
| October 8, 2026, Before Open | |
| Expiry used | November 20, 2026 (43 days out) |
| Spot | $14.19 |
| ATM straddle | $2.84 |
| Implied move | ±20.01% ($11.35 to $17.03) |
| ATM implied vol | 68.8% |
| Put/call open interest | 0.40 |
| Max pain | $15 |
| Net dealer gamma | +$0.00mn per 1% move, LONG GAMMA |
| Heaviest call strike above spot | $17.5 (6 contracts) |
| Street EPS estimate | $-0.12 |
| Street revenue estimate | $0.08bn |
Dealers sit long gamma into the print, which means their hedging leans against the move and tends to compress ANGO between catalysts. That damping disappears the moment the number crosses the tape.
How the stock has reacted before
| Report | Next-day move |
|---|---|
| Q2 2026, Jul 14 | +13.27% |
| Q1 2026, Jun 3 | +9.56% |
| Q4 2025, Jan 6 | -17.46% |
Across the last 3 prints the average absolute reaction is 13.43%, with 2 higher and 1 lower. The best was +13.27% and the worst -17.46%. Options are asking ±20.01%, which is 6.58 points richer than the realised average, the premium seller's case.
Where the stock is trading
| Measure | Level |
|---|---|
| Spot | $14.19 |
| 52-week range | $9.39 to $16.29 |
| Position in that range | 70% |
| From the 52-week high | -12.9% |
| From the 52-week low | +51.1% |
| Past week | -7.7% |
| Past month | -6.8% |
| Past three months | +9.8% |
| 50-day average | $15.45 |
| 200-day average | $12.50 |
How the options market is pricing it
The November 20, 2026 straddle marks $11.35 to $17.03 as the range the options market is paying for into the print, with ATM implied vol at 69% set to drain the morning after. A reaction inside that band hands the edge to premium sellers; a break outside it rewards premium buyers. Historically ANGO has moved 13.43% on earnings against the ±20.01% now implied, so the market is pricing this print richer than the recent average. Which side of that trade is right depends on the number, the guidance and where positioning unwinds.
Read the mechanics behind the crush in our earnings volatility guide, and pull the live memo for ANGO before the print.
Data as of October 8, 2026 from the live option chain, exchange price history and SEC-dated earnings reactions. This is research, not investment advice.
Related: ANGO options memo